Browse the evidence

Intentional weight loss in older adults using anti-obesity medicines (AOMs) improves cardiometabolic outcomes and preserves skeletal muscle strength and bone mineral density, countering the risks of sarcopenia and functional decline.

If you are over 60 and have obesity, intentional weight loss using FDA-approved medications (like semaglutide or tirzepatide) combined with resistance training is safe and effective. It improves heart and metabolic health without necessarily causing frailty, provided you work with a clinician to manage side effects and maintain muscle mass.

Post-ACL reconstruction rehabilitation using Blood Flow Restriction (BFR) with low-load resistance training (30% 1RM) produces significantly greater gains in quadriceps and hamstring muscle strength and knee physical function compared to high-load resistance training (70% 1RM) without occlusion.

If you are in early rehab after ACL surgery, ask your physical therapist about Blood Flow Restriction (BFR) training. It allows you to use light weights (30% of your max) while still getting strong muscle gains, which is safer for your graft than heavy lifting. This method also helps reduce pain and improves knee function faster than standard heavy lifting in the first 3 months.

Triple agonist retatrutide (GLP-1/GIP/glucagon) produces superior weight loss (up to 24.2% at 12mg) compared to dual agonists and GLP-1 monotherapy, driven by synergistic activation of all three receptors.

Retatrutide, a once-weekly injection targeting three gut hormones, has shown unprecedented weight loss (up to 24%) in clinical trials for obesity. While effective, it carries a risk of gastrointestinal side effects like nausea, which are usually manageable by starting at a low dose and increasing slowly. It represents a significant advancement over older GLP-1 drugs.

GLP-1 receptor agonists (including semaglutide, liraglutide, dulaglutide, and tirzepatide) significantly reduce hepatic lipid content and improve liver histology (steatosis, inflammation, and fibrosis) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), primarily through weight loss and direct metabolic modulation.

If you have fatty liver disease (MASLD) and struggle with weight or blood sugar, GLP-1 medications like semaglutide or tirzepatide are highly effective treatments. They don't just help you lose weight; they directly reduce fat in the liver and can reverse inflammation and early scarring. While they are injections and may cause temporary stomach upset, the clinical data shows they significantly improve liver health outcomes compared to placebo.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant weight loss (6–30%+ TBWL) and improve fertility outcomes (spontaneous conception, IVF pregnancy rates) in women with obesity and PCOS when used in the preconception period.

If you have obesity and are trying to conceive, GLP-1 medications (like Wegovy or Zepbound) are highly effective for weight loss and improving fertility, especially if you have PCOS. You must stop taking them 2 months before you try to conceive to ensure the drug is out of your system. Work with your doctor to manage side effects and costs.

Once-daily oral semaglutide (3–14 mg) significantly reduces HbA1c (mean -1.16%-points) and body weight (mean -5.84 kg) in adults with type 2 diabetes over 34–44 weeks, with 47.5% achieving HbA1c < 7.0% and 35.5% achieving composite targets (HbA1c reduction ≥ 1.0%-points plus body weight reduction ≥ 5%).

If you have Type 2 Diabetes and are struggling with blood sugar and weight, oral semaglutide is a proven, once-daily option that can significantly lower your HbA1c and help you lose weight. Most people find it easy to take, and while stomach issues can happen, they are usually mild. It is particularly useful if you want to avoid injections.

Older adults require higher per-meal protein doses (0.40 g/kg) compared to younger adults (0.24 g/kg) to achieve maximal muscle protein synthesis due to anabolic resistance.

If you are over 60, you likely need more protein per meal than you think to build or keep muscle. Aim for about 0.4 grams of high-quality protein per kilogram of your body weight at each main meal (breakfast, lunch, dinner). This is roughly double the amount needed by a 20-year-old to trigger the same muscle-building response. Combine this with resistance exercise for best results.

Once-weekly subcutaneous semaglutide 2.4 mg injection is a cost-effective weight management therapy in the UK compared to diet and exercise alone, yielding an ICER of £14,827/QALY gained.

For patients in the UK with obesity and comorbidities, once-weekly semaglutide 2.4 mg combined with diet and exercise is a cost-effective treatment option approved by NICE. It offers significant health benefits over diet and exercise alone, with a stopping rule to ensure efficacy (5% weight loss at 6 months).

Supplementation with 15g of specific collagen peptides immediately following high-load resistance exercise significantly upregulates gene expression in the PI3K-Akt and MAPK anabolic signaling pathways in human skeletal muscle compared to placebo.

If you perform high-load resistance training, consuming 15g of specific collagen peptides immediately afterward may enhance the activation of key muscle-building signaling pathways (PI3K-Akt and MAPK) in your muscles compared to not taking them. This suggests collagen peptides can play a role in muscle adaptation when paired with exercise, even if they are not a complete protein source like whey.

Semaglutide 2.4 mg is the most cost-effective weight-management pharmacotherapy in Canada compared to standard of care (diet and exercise) and other approved drugs, primarily due to its superior ability to delay or prevent type 2 diabetes, sleep apnea, and cardiovascular events.

For adults in Canada with obesity (BMI ≥30 or ≥27 with comorbidities), Semaglutide 2.4 mg is currently the most cost-effective pharmacological treatment compared to diet/exercise alone or other drugs like Orlistat. It works by acting as a GLP-1 receptor agonist to promote weight loss and improve metabolic health. While it requires weekly injections and has a higher upfront cost, it significantly reduces the long-term risk of type 2 diabetes, cardiovascular events, and sleep apnea, making it a superior value for money in the Canadian healthcare system.

Combination therapy of semaglutide (2.4 mg) and cagrilintide (2.4 mg) (CagriSema) produces weight loss (~15.6%) and HbA1c reduction (~2.2%) comparable to the highest dose of tirzepatide (15 mg) in patients with Type 2 Diabetes.

For patients with Type 2 Diabetes and obesity, a new combination injection (CagriSema) containing semaglutide and cagrilintide (both 2.4 mg weekly) achieves significant weight loss (15.6%) and blood sugar control (HbA1c reduction 2.2%), comparable to the highest dose of tirzepatide. This offers a potent option for those who need both glucose and weight management.

Semaglutide (2.4 mg weekly) and Liraglutide (3 mg daily) are effective pharmacological interventions for obesity-related hypertension, with Semaglutide showing superior weight loss and blood pressure reduction compared to Liraglutide.

If lifestyle changes aren't enough, GLP-1 drugs like Semaglutide (Wegovy) are highly effective. You get a 14.9% weight loss and 6.2 mmHg BP drop on average. It's a once-weekly injection, which is more convenient than daily options.

Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) produce significantly greater weight loss and glycemic control than selective GLP-1 receptor agonists by synergistically targeting both incretin pathways.

If you have T2DM or obesity, dual GLP-1/GIP agonists like tirzepatide are currently the most effective pharmacological option for weight loss and blood sugar control, outperforming older GLP-1 drugs. They are taken as a once-weekly injection. Discuss with your doctor if this advanced therapy is appropriate for your specific health profile.

Post-bariatric pharmacotherapy with GLP-1 receptor agonists (specifically liraglutide) effectively augments weight loss and prevents weight regain in patients who have undergone Roux-en-Y gastric bypass or sleeve gastrectomy.

If you have had bariatric surgery and are regaining weight, talk to your doctor about adding a GLP-1 medication like liraglutide. It is taken as a daily injection, starting at a low dose to minimize side effects like nausea, and can help you lose additional weight or stop regaining it. This is a standard, evidence-based next step when surgery alone is not enough.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) induce significant weight loss (≥10%) and reduce major adverse cardiovascular events (MACE) in patients with obesity, outperforming conventional anti-obesity drugs and lifestyle modification alone.

If you have obesity and are at risk for heart disease, GLP-1 receptor agonists like semaglutide or liraglutide are currently the most effective pharmacological options for achieving significant weight loss (often >10%) and reducing cardiovascular risk. Unlike older weight-loss drugs or lifestyle changes alone, these medications address the hormonal drivers of weight regain and offer specific heart benefits. However, they require long-term use to maintain results, and treatment should be discussed with a healthcare provider to weigh benefits against costs and side effects.

Tirzepatide, a GIP/GLP-1 receptor agonist, achieves unprecedented reductions in HbA1c and clinically significant weight loss in Type 2 Diabetes patients, with a substantial proportion achieving normoglycemia without hypoglycemia.

Tirzepatide is a once-weekly injection that significantly lowers blood sugar and promotes substantial weight loss in people with Type 2 Diabetes, often without causing low blood sugar. It is designed to be started at a low dose and gradually increased to minimize side effects like nausea. This treatment challenges the old view that effective diabetes management requires insulin or causes weight gain.

Multi-receptor incretin drugs (Tirzepatide, Retatrutide, Mazdutide, Survodutide) produce substantial weight loss (>8kg) and glycemic control (HbA1c reduction >1%) in adults with overweight/obesity, with non-diabetic populations showing more pronounced effects than those with type 2 diabetes.

If you have overweight or obesity, multi-receptor incretin drugs like Tirzepatide or Retatrutide are highly effective for significant weight loss (often >10kg) and improving blood sugar control. These benefits are even more pronounced if you do not have type 2 diabetes. While gastrointestinal side effects are common, serious safety risks are not significantly higher than placebo. Consult a healthcare provider to determine if these medications are appropriate for your specific health profile.

Pharmacological interventions with GLP-1 receptor agonists (e.g., semaglutide 2.4 mg, tirzepatide) and SGLT2 inhibitors promote weight loss and improve glycemic control, contributing to diabetes remission and reduced cardiovascular/renal risks.

If lifestyle changes alone aren't enough to control your diabetes or help you lose weight, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are weekly injections that help you lose weight and can put type 2 diabetes into remission for many people. They also protect your heart and kidneys. They are not just 'diet pills' but powerful tools for managing the disease.

Semaglutide 2.4 mg combined with diet and exercise is cost-effective for adults with obesity (BMI ≥ 30 kg/m²) and comorbidities in Portugal, yielding 0.098 QALYs gained at an ICER of 13,459 EUR per QALY compared to diet and exercise alone.

For patients with obesity and comorbidities in Portugal, adding semaglutide 2.4 mg to diet and exercise is a cost-effective strategy that improves quality-adjusted life years compared to diet and exercise alone, particularly for those with BMI ≥ 30 kg/m².

Achieving early weight loss of ≥10% body weight in newly diagnosed type 2 diabetes significantly increases the likelihood of diabetes remission and sustains glycaemic improvements compared to losing <10%.

For newly diagnosed type 2 diabetes, aiming for a 10% body weight loss within the first five years is a critical threshold. This specific magnitude of loss is strongly associated with a 4-fold increase in the chance of achieving diabetes remission and sustained lower HbA1c levels compared to smaller weight losses.

GLP-1 Receptor Agonists (specifically Semaglutide) induce significant weight loss (10-15%) and improve metabolic and endocrine markers (including menstrual regularity and insulin sensitivity) in women with PCOS, although long-term sustainability requires continued treatment.

Semaglutide (a GLP-1 RA) is an effective treatment for women with PCOS who are obese and haven't succeeded with lifestyle changes alone. It promotes significant weight loss (approx. 11-15 kg) and can restore menstrual regularity and improve insulin sensitivity. However, stopping the medication often leads to partial weight regain, suggesting it may need to be a long-term therapy for sustained benefits.

Tirzepatide, a GLP-1/GIP receptor co-agonist, produces superior weight loss and glycemic control compared to selective GLP-1 receptor agonists and insulin in patients with type 2 diabetes.

If you have type 2 diabetes, tirzepatide is a once-weekly injection that lowers blood sugar and helps you lose more weight than older diabetes medications. It is generally well-tolerated, though you may experience gastrointestinal side effects. Discuss with your doctor if this once-weekly option is right for you.

Tirzepatide achieves body weight loss of ≥ 5% significantly faster than semaglutide 1 mg in patients with type 2 diabetes.

If your goal is weight loss alongside blood sugar control, tirzepatide (10 or 15 mg) will likely get you to a 5% body weight reduction in about 12 weeks, which is half the time it takes with semaglutide 1 mg. This benefit persists despite the slower dose escalation schedule required to manage side effects.

Semaglutide 2.4 mg administered subcutaneously once-weekly produces significant body weight reduction (mean 12.2 kg or 11.8%) and improves cardiometabolic parameters in adults with obesity, with real-world evidence confirming efficacy similar to randomized controlled trials.

Semaglutide 2.4mg once weekly is a highly effective treatment for obesity, producing an average 12kg weight loss when combined with lifestyle changes. Real-world data confirms it works as well as in clinical trials. Be aware of common side effects like nausea, which often subside, and discuss cost-effectiveness with your provider as it varies by region and insurance.